Cue biopharma reports fourth quarter and full year 2024 financial results and business highlights

Boston, march 31, 2025 (globe newswire) -- - cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific t cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results.
CUE Ratings Summary
CUE Quant Ranking